1. Home
  2. UNCY vs MSSA Comparison

UNCY vs MSSA Comparison

Compare UNCY & MSSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UNCY
    SELLHOLDBUYas of a day ago
  • MSSA
    SELLHOLDBUYas of 2 days ago
  • Stock Information
  • Founded
  • UNCY 2016
  • MSSA 2021
  • Country
  • UNCY United States
  • MSSA United States
  • Employees
  • UNCY N/A
  • MSSA N/A
  • Industry
  • UNCY Biotechnology: Pharmaceutical Preparations
  • MSSA
  • Sector
  • UNCY Health Care
  • MSSA
  • Exchange
  • UNCY Nasdaq
  • MSSA NYSE
  • Market Cap
  • UNCY 58.7M
  • MSSA N/A
  • IPO Year
  • UNCY 2021
  • MSSA 2022
  • Fundamental
  • Price
  • UNCY $0.55
  • MSSA $12.80
  • Analyst Decision
  • UNCY Strong Buy
  • MSSA
  • Analyst Count
  • UNCY 3
  • MSSA 0
  • Target Price
  • UNCY $6.50
  • MSSA N/A
  • AVG Volume (30 Days)
  • UNCY 929.0K
  • MSSA 482.0
  • Earning Date
  • UNCY 05-12-2025
  • MSSA 01-01-0001
  • Dividend Yield
  • UNCY N/A
  • MSSA N/A
  • EPS Growth
  • UNCY N/A
  • MSSA N/A
  • EPS
  • UNCY N/A
  • MSSA N/A
  • Revenue
  • UNCY N/A
  • MSSA N/A
  • Revenue This Year
  • UNCY N/A
  • MSSA N/A
  • Revenue Next Year
  • UNCY $888.72
  • MSSA N/A
  • P/E Ratio
  • UNCY N/A
  • MSSA $88.84
  • Revenue Growth
  • UNCY N/A
  • MSSA N/A
  • 52 Week Low
  • UNCY $0.20
  • MSSA $11.10
  • 52 Week High
  • UNCY $1.60
  • MSSA $14.48
  • Technical
  • Relative Strength Index (RSI)
  • UNCY 41.12
  • MSSA 88.42
  • Support Level
  • UNCY $0.60
  • MSSA $12.08
  • Resistance Level
  • UNCY $0.64
  • MSSA $12.20
  • Average True Range (ATR)
  • UNCY 0.05
  • MSSA 0.07
  • MACD
  • UNCY -0.01
  • MSSA 0.05
  • Stochastic Oscillator
  • UNCY 9.86
  • MSSA 53.33

Stock Price Comparison Chart: UNCY vs MSSA

UNCY
MSSA
October2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025April012345678910111213UNCY VS MSSA

About UNCY Unicycive Therapeutics Inc.

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use